Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


In the December 2018 issue, the News Analysis “Radioactive drugs emerge from the shadows to storm the market” reversed the descriptions of Actinium Pharmaceuticals' Iomab-B and Nordic Nanovector's 177Lu-lilotomab satetraxetan (Betalutin). Iomab-B uses iodine-131 to destroy the bone marrow ahead of stem cell transplantation and Betalutin directs lutetium-177 to CD45-expressing B cells in follicular lymphoma.

In the October 2018 issue, the News Feature “The virome hunters” described the work of the PREDICT project incorrectly, and the associated citation was incorrect. The text that read “PREDICT scientists have sampled more than 70,000 animals and people in over 30 countries with high zoonotic disease risks, and the researchers have reported on the discovery of 1,000 virus species with the potential to infect human beings5” has been changed to “PREDICT scientists have sampled more than 70,000 animals and people in over 30 countries at high-risk interfaces and, using consensus PCR, have discovered close to 1,000 new virus species. In bats, for example, which are now believed to be the evolutionary source of viruses such as SARS and MERS, the group detected sequences from 91 coronaviruses in 20 countries5.” Ref. 5 has been changed from Olival, K.J. et al. Nature 546, 646–650 (2017) to Anthony, S.J. et al. Virus Evol. 3, vex012 (2017).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

CORRECTIONS. Nat Biotechnol 37, 11 (2019).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing